Compare Microsoft (MSFT) vs TG Therapeutics Inc (TGTX) Price & Performance

Microsoft (MSFT) trades at $493.95, down 1.15% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 surpassing expectations of $4.24. Revenue growth remains solid, reaching $281.72 billion in 2025, while profitability metrics like a 40.31% net income margin and 34.04% ROE highlight operational efficiency. Analyst sentiment is overwhelmingly positive, with an 80.49% buy rating and a consensus price target of $560.43.

The outlook for MSFT is favorable, driven by AI leadership and cloud momentum, though risks include rising capital expenditures and competitive pressures. Earnings growth and Azure expansion are key catalysts for upside, while macroeconomic volatility and geopolitical tensions pose near-term headwinds. The stock's valuation at a P/E of 27.52 appears reasonable given its growth trajectory, supporting a bullish investment case for long-term holders.

TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.

The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.